Facebook
Twitter
LinkedIn
Forward
Improving Biomarker Driven Precision Therapy in NSCLC: Management Considerations for EGFR-Positive NSCLC: Common Mutations, Atypical Mutations, and Exon 20 Insertion (12/13/2022)
December 13, 2022 5-6pm ET
To claim your CME or CNE credit, please click on take course and follow the instructions. Pharmacists will be emailed instructions on how to claim their credit.
Goals, Gaps in Practice, and Learning Objectives
Biomarker based testing and precision medicine-based approaches have become a standard to guide treatment decisions for advanced non-small cell lung cancer (NSCLC) and are crucial even for early-stage patients. There are several barriers that prevent optimal testing for patients, but the discovery of novel molecular targets and subsequent development of targeted therapies make it critical to find ways to overcome these barriers. As treatment progresses, there is a potential to develop resistance mechanisms to commonly used targeted therapies; these new targets are identified by the integration of precision medicine. Additionally, further research has revealed differing features even within the EGFR mutated NSCLC (e.g., atypical/uncommon mutations such as exon 18 mutations and exon 20 insertion) that warrant a modified approach to improve care for patients.
It is imperative for all members of the lung cancer treatment team (oncologists, pathologists, pharmacists, nurse practitioners, nurses, and physicians’ assistants) to understand this data and recognize the complexity of managing these patients using a precision medicine based approach in both first line and subsequent line therapies.
At this webinar, learn clinical pearls needed to attain best outcomes for your patients with these mutations in a case-based conversation with expert faculty.
- Overview of NSCLC and Transition Towards Biomarker Based Testing
- Discussing the evolving role of adjuvant targeted treatment in EGFR-mutated NSCLC
- Discuss best practices for treating patients with EGFR-mutated NSCLC; including exon 18 mutations and exon 20 insertion
- Review clinical data for novel therapy approved and/or with evolving data
This program is supported by an educational grant from Pfizer Inc.
Target Audience
The primary audience targeted with this educational series includes the lung cancer care team. This encompasses medical oncologists, pathologists, interventional radiologists, pharmacists, nurse practitioners, physicians’ assistants, and nurses involved with the care of patients with NSCLC.
Learning Objectives
At the end of this session, attendees will be able to:
- Discuss the evolving role of adjuvant targeted treatment in EGFR-mutated NSCLC
- Discuss best practices for treating patients with EGFR-mutated NSCLC; including exon 18 mutations and exon 20 insertion
- Review clinical data for novel therapy approved and/or with evolving data
This session will take place virtually through Zoom on Tuesday December 13th, 2022 from 5:00-6:00pm EST.
Register directly through Zoom here: https://bostonu.zoom.us/webinar/register/WN_yFvAl1MjQmyJFsprvxCPlA
Speakers
Jasmine Patel, PharmD, BCOP
Clinical Pharmacy Coordinator – Hematology/Oncology
Boston Medical Center
Dr. Patel is a clinical pharmacy coordinator in the outpatient hematology/oncology clinic at Boston Medical Center and is currently the program director for the PGY2 residency program. In her first year at the institution, Jasmine co-led an initiative with our lead breast cancer oncologist (Dr. Naomi Ko, MD, MPH) to improve adherence and toxicity management of patients treated with oral chemotherapy for metastatic breast cancer. She was additionally awarded "Resident of the Year" for her dedication to her oncology patients and the pharmacy profession. Dr. Patel runs day-to-day pharmacy efforts by routinely calling and managing patients and assisting with PRO documentation within our EMR.
Speaker receives grant funding from Pfizer Inc. for breast cancer research.
Bhavesh Shah R.Ph, BCOP
Chief Pharmacy Officer for Specialty and Hematology/Oncology Pharmacy Services
Boston Medical Center Health System
Bhavesh Shah, R.Ph, BCOP, earned a bachelor of science in pharmacy degree at Massachusetts College of Pharmacy and Health Sciences subsequent to receiving a biochemistry degree from Loyola University Chicago. A board-certified oncology pharmacist, Mr. Shah is presently the Chief Pharmacy Officer for Specialty and Hematology/Oncology Pharmacy Services at Boston Medical Center Health System. In this role, he is responsible for the clinical, research, payor and manufacturer contracting and operational efficiency of the cancer center, specialty pharmacy, and various ambulatory specialty areas. Mr. Shah also oversees clinical support for specialty programs for a regional managed care medicaid plan with over 400,000+ lives and $550 million service line.
He has research experience is in COVID-19, biosimilars, cancer-related anorexia and cachexia syndrome, prevention of chemotherapy-induced nausea and vomiting, treatment of iron deficiency anemia, lung cancer digital adherence technology, immune thrombocytopenia purpura, and inflammatory bowel disease. He is a reviewer for the Annals of Pharmacotherapy, American Journal of Health System Pharmacy and has written articles in the Journal of Oncology Pharmacy Practice, Supportive Care in Cancer, and Biology of Blood and Marrow Transplantation. Mr. Shah has presented both nationally and internationally on biosimilars, specialty pharmacy arena, 340b, and the field of hematology/oncology pharmacy.
Speaker receives grant/research support from Pfizer, Alexion, Fujifilm and Rigel
Umit Tapan, MD
Thoracic Medical Oncologist
Co-Director, Thoracic Oncology Program, Boston Medical Center
Assistant Professor of Medicine, Boston University Chobanian & Avedisian School of Medicine
Dr. Tapan is an Assistant Professor of Medicine at Boston University School of Medicine and a practicing Thoracic Oncologist at Boston Medical Center. He currently co-leads BMC thoracic oncology program and is the site-PI for clinical trials in thoracic malignancies. As a productive clinical researcher Dr. Tapan has authored numerous publications. His previous research efforts focusing on the role of c-cbl in pathophysiology of colorectal cancer have been published in prestigious journals. Dr. Tapan has been interested in racial disparity in cancer care since early years of his career and he has previously shown that African American patients with colorectal cancer have significantly lower survival despite equal access to care. His current research interests are racial disparities in lung cancer care, access to targeted treatments and immune checkpoint inhibitors in vulnerable populations. Most recently looking at disparities in chemotherapy receipt in extensive stage small cell lung cancer. (https://www.jtocrr.org/article/S2666-3643(20)30155-7/fulltext)
Speaker is an outside consultant for GSK, receives grant/research support from Pfizer.
Planning Committee
Dana F. Price, MS, CHCP
Grants and Development Manager
Continuing Medical Education Office Boston University School of Medicine
David Hughes, PharmD, BCOP
Course Director
Clinical Pharmacy Manager Hematology/Oncology
Boston Medical Center
Jasmine Patel, PharmD
Clinical Pharmacy Specialist – Hematology/Oncology
Boston Medical Center
Umit Tapan, MD
CME Course Director
Assistant Professor of Medicine, Department of Medicine, Boston University School of Medicine
Elizabeth Tiani, AGACNP
NCPD Course Advisor
Instructor of Medicine, Medical Oncology
BUSM/BMC
Carmela A. Townsend, DNP, MS/MBA, RN
Accredited Provider Activity Director
Continuing Medical Education Office Boston University School of Medicine
Planners have nothing relevant to disclose.
CME Program Manager: Claire P. Grimble, CMP
Boston University Chobanian & Avedisian School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Boston University Chobanian & Avedisian School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Boston University Chobanian & Avedisian School of Medicine Continuing Nursing Education is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
Contact Hours: 1.25 of which 1.25 is eligible for pharmacology credit.
The University of Rhode Island College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge-based educational activity. Pharmacists will receive 1.0 contact hour (0.10 CEUS) for the educational activity. No partial credit is available.
UNIVERSAL ACTIVITY NUMBERS (UAN) 0060-9999-22-095-L01-P
Available Credit
- 1.00 AMA PRA Category 1 Credit™
Boston University Chobanian & Avedisian School of Medicine designates this Live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.25 ANCC
- 1.25 ANCC Pharmacology
- 1.00 Participation
Please register directly through Zoom here: https://bostonu.zoom.us/webinar/register/WN_yFvAl1MjQmyJFsprvxCPlA